Skip to main content
SpringerLink
Log in

The diagnostic utility of somatostatin receptor scintigraphy in oncology

  • Review
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Somatostatin receptor scintigraphy (SRS) with the diethylenetriaminopentaacetic-acid-conjugated somatostatin analogue [111In-DTPA-d-Phe1] octreotide, also known as111In-pentetreotide, is a new non-invasive modality for the evaluation of tumours that express receptors for somatostatin. These receptors are present on neuroendocrine and other tumours including lymphomas and some breast cancers. In oncology SRS is a promising diagnostic tool for localizing primary tumours, staging, control and follow-up after therapy, and for identification of patients who may benefit from therapy with unlabelled octreotide or, in the future, with radiolabelled octreotide. In the past few years many small and large studies investigating various aspects of SRS have been reported. In this review the value of SRS in the management of individual tumour types is explored. For many tumours the best sensitivity in lesion detection is only achieved by very careful imaging after the administration of at least 200 MBq111In-pentetreotide. On the basis of the current experience the main value of SRS in oncology is in the staging and evaluation of gastroenteropancreatic tumours, paragangliomas, small-cell lung cancer and lymphomas. Promising areas for SRS are the evaluation of breast cancer, non-medullary thyroid cancer and melanoma, and initial results with targeted radionuclide therapy using radiolabelled octreotide have been reported.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

SRS :

somatostatin receptor scintigraphy

DTPA :

diethylenetriaminopentaacetic acid

SPET :

single-photon-emission tomography

CT :

computed tomography

MRI :

magnetic resonance imaging

TSH :

thyroid-stimulating hormone

MIBG :

m-iodobenzyl-guanidine

MTC :

medullary thyroid carcinoma

SCLC :

small-cell lung carcinoma

EGF :

epidermal growth factor

References

  • Adrian HJ, Dorr U, Bach D, Bihl H (1993) Biodistribution of111In-pentetreotide and dosimetric considerations with respect to somatostatin receptor expressing tumor burden. Horm Metab Res [Suppl] 27:18–23

    Google Scholar 

  • Anker-Lugtenburg PJ van den, Krenning EP, Oei HY, Gerrits CHJ, Vanhagen PM, Reubi J-C, Lamberts SWJ, Löwenberg B (1994) The role of somatostatin receptor scintigraphy (SRS) in the initial staging of malignant lymphoma. J Nucl Med 35:132P

    Google Scholar 

  • Arndt JW, Lamers CBHW, Jansen JBMJ, Pauwels EKJ (1993) De waarde van somatostatine receptor scintigrafie (111In-Octreoscan) bij patienten met gastrointestinale en pancreas apudoma's. Nucl Geneeskd Bull 15:69–70

    Google Scholar 

  • Bajc M, Ingvar C, Persson B, Tibblin S, Karlsson S-E, Edenbradt L, Palmer J (1993) Dynamic octreotide scintigraphy in neuroendocrine tumours. Eur J Nucl Med 20:843

    Google Scholar 

  • Bakker WH, Krenning EP, Breeman WAP, Koper JW, Kooij PPM, Reubi JC, Klijn JG, Visser TJ, Docter R, Lamberts SWJ (1990) Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. J Nucl Med 31:1501–1509

    PubMed  Google Scholar 

  • Bakker WH, Albert R, Bruns C, Breeman WAP, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW, Lamberts SWJ, Visser TJ, Krenning EP (1991a) [111In-DTPA-d-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 49:1583–1591

    PubMed  Google Scholar 

  • Bakker WH, Krenning EP, Reubi JC, Breeman WAP, Setyono-Han B, Jong M de, Kooij PPM, Bruns C, Hagen PM van, Marbach P, Visser TJ, Pless J, Lamberts SWJ (1991b) In vivo application of [111In-DTPA-d-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 49:1593–1601

    PubMed  Google Scholar 

  • Bakker WH, Breeman WA, Hofland LJ, Jong M de, Pluijm ME van der, Visser TJ, Lamberts SW, Krenning EP (1994) Labelling of somatostatin (SS) analogs with I-131: an option for radiotherapy of SS-receptor-positive tumours? Eur J Nucl Med 21:S 202

    Google Scholar 

  • Bares R, Dempke W, Handt S, Galonska P, Buell U, Osieka R, Mittermaier C (1993a) Somatostatin receptor scintigraphy (SRS) in malignant lymphoma: first results and comparison with findings of CT and FDG-PET. Eur J Nucl Med 20:884

    Google Scholar 

  • Bares R, Dempke W, Handt S, Galonska P, Buell U, Osieka R, Mittermaier C (1993b) Somatostatin receptor scintigraphy (SRS) in malignant lymphoma (ML): first results and comparison with CT and positron-emission-tomography (PET) with fluorine-18 labeled deoxyglucose (FDG). J Nucl Med 34:164P

    Google Scholar 

  • Bauer W, Briner U, Döpfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982) SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133–1140

    PubMed  Google Scholar 

  • Becker W, Schrell U, Lohner W, Thieraf P, Buchfelder M, Wolf F (1993a) In-111-octreotide-SPECT in patients with brain and pituitary tumors. Eur J Nucl Med 20:883

    Google Scholar 

  • Becker W, Wendler J, Lohner W, Gramatzki M, Kalden JR, Wolf F (1993b) Transferrin (Ga67) versus somatostatin (In-111-octreotide) receptor scintigraphy in patients with lymphomas. Eur J Nucl Med 20:938

    Google Scholar 

  • Bell GI, Reisine T (1993) Molecular biology of somatostatin receptors. Trends Neurosci 16:34–38

    PubMed  Google Scholar 

  • Berná L, Torres G, Carrió I, Cabezas R, Estorch M, Guiu M, Mora J (1993) Octreotide-In111 in the detection of recurrences from medullary thyroid carcinoma. Eur J Nucl Med 20:972

    Google Scholar 

  • Bombardieri E, Crippa F, Chiti F, Seregni E, Cataldo I, Soresi E, Boffi R, Buraggi GL (1994) Scintigraphy of small cell lung cancer (SCLC) using 111-In DTPA-octreotide. Eur J Nucl Med 21:731

    Google Scholar 

  • Bong SB, Laan JG van der, Louwes H, Schuurman JJ (1994) Clinical experience with somatostatin receptor imaging in lymphoma. Semin Oncol 21 [Suppl 13]:46–50

    PubMed  Google Scholar 

  • Bootsma AH, Eijck C van, Schouten KK, Reubi JC, Waser B, Foekens JA, Pel R van, Zwarthoff EC, Lamberts SWJ, Klein A de (1993) Somatostatin receptor-positive primary breast tumors: genetic, patient and tumor characteristics. Int J Cancer 54:357–362

    PubMed  Google Scholar 

  • Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R (1973) Hypothalamic polypeptide that inhibits the secretion immunoreactive pituitary growth factor. Science 179:77–79

    PubMed  Google Scholar 

  • Breeman WAP, Hofland LJ, Pluijm M van der, Koetsveld PM van, Jong M de, Setyono-Han B, Bakker WH, Kwekkeboom DJ, Visser TJ, Lamberts SWJ (1994a) A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-d-Phe1]-octreotide. Eur J Nucl Med 21: 328–335

    PubMed  Google Scholar 

  • Breeman WAP, Vanhagen MP, Visser H, Pluijm MP an der, Koper JW, Setyono Han B, Hazenberg MP, Bakker WH, Kwekkeboom DJ, Lamberts SWJ, Visser TJ, Krenning EP (1994b) Substance P (SP) receptor scintigraphy: initial studies in vitro and in rats. Eur J Nucl Med 21:S47

    Google Scholar 

  • Briele B, Hotze AL, Bode U, Schulte T, Gruenwald F, Biersack HJ (1992) In-111 labeled octreotide (In-Oct) for tumor imaging. Initial results in neuroblastoma. Eur J Nucl Med 19:737

    Google Scholar 

  • Bruin TWA de, Kwekkeboom DJ, Verlaat JW van't, Reubi JC, Krenning EP, Lamberts SWJ, Croughs RJ (1992) Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab 75:1310–1317

    PubMed  Google Scholar 

  • Bruno JF, Xu Y, Song J, Berelowitz M (1992) Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proc Natl Acad Sci USA 89:11 151–11 155

    Google Scholar 

  • Cai RZ, Szoke B, Lu R, Fu D, Redding TW, Schally AV (1986) Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci 83:1896–1900

    PubMed  Google Scholar 

  • Clarke SEM, Lazarus CR, Wraight P, Sampson C, Maisey MN (1988) Pentavalent [99m Tc]DMSA, [131I]MIBG, and [99m Tc] MDP-an evaluation of three techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 29:33–38

    PubMed  Google Scholar 

  • D'Orisio SM, Hauger M, Cecalupo AJ (1994) Somatostatin receptors in neuroblastoma: diagnostic and therapeutic implications. Semin Oncol 21 [Suppl 13]:33–37

    Google Scholar 

  • Dongen A van, Verhoeff NPLG, Bemelman F, Royen EA van (1992) Somatostatin receptor imaging with111In-pentatreotide for whole body studies and high resolution SPECT. Eur J Nucl Med 19:679

    Google Scholar 

  • Donovan DT, Gagel RF (1990) Medullary thyroid carcinoma and the multiple endocrine neoplasia syndromes. In: Falk SA (ed) Thyroid disease: endocrinology, surgery, nuclear medicine, and radiology. Raven, New York, pp 501–525

    Google Scholar 

  • Dop FJ (1994) The European multicentre clinical trial group on GEP neuroendocrine tumours. J Nucl Med 35:96P

    Google Scholar 

  • Dörr U, Frank-Raue K, Buhr HJ, Hehrmann R, Iser G, Bihl H (1993a) Localization of recurrences from medullary thyroid carcinoma by somatostatin receptor scintigraphy. Eur J Nucl Med 20:843

    Google Scholar 

  • Dörr U, Frank-Raue K, Raue F, Sautter-Bihl ML, Guzman G, Buhr HJ, Bihl H (1993b) The potential value of somatostatin receptor scintigraphy in medullary thyroid carcinoma. Nucl Med Commun 14:439–445

    PubMed  Google Scholar 

  • Dörr U, Räth U, Bach D, Bihl H (1993c) Detection of neuroendocrine tumors of the gastrointestinal tract by means of somatostatin receptor scintigraphy. J Nucl Med 34:97P-98P

    Google Scholar 

  • Dörr U, Wurm K, Horing E, Guzman G, Rath U, Bihl H (1993d) Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs. Horm Metab Res [Suppl] 27:36–43

    Google Scholar 

  • Dörr U, Würstlin S, Frank-Raue K, Raue F, Hehrmann R, Iser G, Scholz M, Guhl L, Buhr HJ, Bihl H (1993e) Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: a comparative study. Horm Metab Res [Suppl] 27:48–55

    Google Scholar 

  • Eijck CH van, Bruining HA, Reubi JC, Bakker WH, Oei HY, Krenning EP, Lamberts SWJ (1993) Use of isotope-labeled somatostatin analogs for visualization of islet cell tumors. World J Surg 17:444–447

    PubMed  Google Scholar 

  • Eijck CH van, Krenning EP, Bootsma A, Oei HY, Pet R van, Lindemans J, Jeekel J, Reubi JC, Lamberts SWJ (1994), Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343: 640–643

    PubMed  Google Scholar 

  • Faglia G, Bazzoni N, Spada A, Arosio M, Ambrosi B, Spinelli F, Sara R, Bonino C, Lunghi F (1991) In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204-090). J Clin Endocrinol Metab 73:850–856

    PubMed  Google Scholar 

  • Fischman AJ, Babich JW, Strauss HW (1993) A ticket to ride: peptide radiopharmaceuticals. J Nucl Med 34:2253–2263

    PubMed  Google Scholar 

  • Foekens JA, Portengen H, van Putten WL, Trapman AM, Reubi JC, Alexieva-Figusch J, Klijn JG (1989) Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002–7009

    PubMed  Google Scholar 

  • Giammarile F, Lumbroso J, Schlumberger M, Tenenbaum F, Baudin E, Parmentier C (1995) Interest of somatostatin receptors scintigraphy for imaging differentiated thyroid carcinoma tumor sites. J Nucl Med 36:14P

    Google Scholar 

  • Giannakenas C, Apostolopoulos A, Tselfes, J, Mastorakou A, Likaki E, Tzorakoeleftherakis E, Mirilas P, Gorilas T, Vassilakos PJ (1994) In-vivo scintigraphic imaging of breast cancer utilizing the radiolabeled somatostatin analogue octreotide. Eur J Nucl Med 21:748

    Google Scholar 

  • Gils APG van, Erkel AR van, Falke, THM, Pauwels EKJ (1994) Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Eur J Nucl Med 21:239–253

    PubMed  Google Scholar 

  • Gorden P, Comi RJ, Maton PN, Go VL (1989) NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 110:35–50

    PubMed  Google Scholar 

  • Haldemann AR, Rösler H, Barth A, Waser B, Geiger L, Godoy N, Markwalder RV, Seiler RW, Sulzer M, Reubi JC (1995) Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability. J Nucl Med 36:403–410

    PubMed  Google Scholar 

  • Hammond PJ, Arka A, Peters AM, Bloom SR, Gilbey SG (1994) Localization of metastatic gastroenteropancreatic tumours by somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]-octreotide. Q J Med 87:83–88

    PubMed  Google Scholar 

  • Herder WW de, Krenning EP, Malchoff CD, Hofland LJ, Reubi JC, Kwekkeboom DJ, Oei HY, Pols HAP, Bruining HA, Nobels FRE, Lamberts SWJ (1994) Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med 96:305–312

    PubMed  Google Scholar 

  • Hertel A, Seipp C, Baum RP, Maul FD, Lang C, Class D, Marquardt G, Rosenthal D, Kranert WT, Schlote W, Lorenz R (1993) Imaging of brain tumors with thallium, somatostatin-analog and anti-EGF antibody for evaluation of receptors and metabolism. Eur J Nucl Med 20:962

    Google Scholar 

  • Hoefnagel CA (1994) Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 21:561–581

    PubMed  Google Scholar 

  • Hoefnagel CA, Delprat CC, Zanin DEA, Schoot JB van der (1988) New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma. Clin Nucl Med 13:159–165

    PubMed  Google Scholar 

  • Hoefnagel CA, Valdés Olmos RA, Rankin EM, Israëls SP (1995) Melanoma detection using Indium-111 pentetreotide. Eur J Nucl Med 22:753

    Google Scholar 

  • Höring E, Räth U, Rücker S, Gaisberg U von, Meincke J, Walendzik J, Dörr U, Bihl H (1994) Somatostatinrezeptor-Szintigraphie in der Primärdiagnostik und Nachsorge bei Gastrinomen. Dtsch Med Wochenschr 119:367–374

    PubMed  Google Scholar 

  • Ivancevic V, Nauck C, Sandrock D, Kögler A, Munz DL, Creutzfeld W, Emrich D (1993) Are 24-hour images in 111-In-pentetreotide scintigraphy of gastroenteropancreatic tumours (GEP) necessary? Eur J Nucl Med 20:846

    Google Scholar 

  • Ivancevic V, Nauck C, Wörmann B, Sandrock D, Hiddemann W, Munz DL, Emrich D (1994) Somatostatin receptor scintigraphy in Hodgkin-(HL) and non-Hodgkin lymhomas (NHL). J Nucl Med 35:132P

    Google Scholar 

  • Jamar, F, Leners N, Fiasse R, Pauwels S (1992) Morphological imaging and somatostatin receptor scintigraphy gastro-entero-pancreatic (GEP) tumours — a comparative study. Eur J Nucl Med 19:737

    Google Scholar 

  • Jamar F, Fiasse R, Leners N, Pauwels S (1995) Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 36:542–549

    PubMed  Google Scholar 

  • Jong M de, Breeman WAP, Bernard BF, Rolleman EJ, Hofland LJ, Visser TJ, Setyono-Han B, Bakker WH, Pluijm ME van der, Krenning EP (1995) Evaluation in vitro and in rats of 161 Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. Eur J Nucl Med 22:608–624

    PubMed  Google Scholar 

  • Joseph K, Stapp J, Reinecke J, Höffken H, Benning R, Neuhaus C, Trautmann ME, Schwerk WB, Arnold R (1992) Rezeptorszintigraphie bei endokrinen gastroenteropankreatischen Tumoren. Dtsch Med Wochenschr 117:1025–1028

    PubMed  Google Scholar 

  • Kau RJ, Wagner-Manslau C, Saumweber DM, Arnold W (1994) Nachweis von Somatostatinrezeptoren in Tumoren des Kopf-Hals-Bereiches und ihre kliniche Bedeutung. Laryngorhinootologie 73:21–26

    PubMed  Google Scholar 

  • Kerviler E de, Cadiot G, Lebtahi R, Faraggi M, Le Gudulec D, Mignon M (1994) Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. Eur J Nucl Med 21:1191–1197

    PubMed  Google Scholar 

  • King CM, Reznek RH, Bomanji J, Ur E, Britton KE, Grossman AB, Besser GM (1993) Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study. Clin Radiol 48:386–391

    PubMed  Google Scholar 

  • Kirsch C-M, Pawel J von, Grau I, Tatsch K (1994) Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma. Eur J Nucl Med 21:1318–1325

    PubMed  Google Scholar 

  • Kortüm S, Chen T, Rausch V (1993) Szintigraphy with In-111 octreotide in the management of patients with small cell bronchial carcinoma. Eur J Nucl Med 20:884

    Google Scholar 

  • Krausz Y, De Jong RBJ, Glaser B (1993) Somatostatin-receptor scintigraphy of endocrine tumors. J Nucl Med 1993:164P

  • Krausz Y, Ish-Shalom S, Jong RBJ de, Shibley N, Lapidot M, Maaravi I, Glaser B (1994) Somatostatin-receptor imaging of medullary thyroid carcinoma. Clin Nucl Med 19:416–421

    PubMed  Google Scholar 

  • Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SWJ (1989) Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1:242–244

    PubMed  Google Scholar 

  • Krenning EP, Kooij PPM, Bakker WH, Breeman WAP, Postema PTE, Kwekkeboom DJ, Oei HY, Jong M de, Visser TJ, Reijs AEM, Lamberts SWJ (1994) Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-d-Phe1]-octreotide. A case history. Ann NY Acad Sci 733:496–506

    PubMed  Google Scholar 

  • Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooij PPM, Oei HY, Hagen M van, Postema PTE, Jong M de, Reubi JC, Visser TJ, Reijs AEM, Hofland LJ, Koper JW, Lamberts SWJ (1993a) Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731

    PubMed  Google Scholar 

  • Krenning EP, Kwekkeboom DJ, Reubi JC, Hagen PM van, Eijck CH van, Oei HY, Lamberts SWJ (1993b) 111In-octreotide scintigraphy in oncology. Digestion 1:84–87

    Google Scholar 

  • Krenning EP, Kwekkeboom DJ, Lamberts SWJ, Pauwels S, Kvols L, Reubi JC (1995) Somatostatin receptor scintigraphy. In: Freeman LM (ed) Nuclear medicine annual 1995. Raven, New York, pp 1–50

    Google Scholar 

  • Kroiss A, Auininger C, Schüller J, Neumayr A (1993a) Imaging and therapy control of tumours by receptor scintigraphy with 111In-octreotide. Nucl Med Commun 14:255

    Google Scholar 

  • Kroiss A, Böck F, Auinger C, Perneczky G, Kleinpeter G (1993b) Localization of brain tumors with an In-111 labeled somatostatin-analogue, and Tc-99m pertechnetate. Eur J Nucl Med 20:974

    Google Scholar 

  • Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y (1994) Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 93:1321–1325

    PubMed  Google Scholar 

  • Kvols LK (1993) Somatostatin-receptor imaging of human malignancies: a new era in the localization, staging, and treatment of tumors. Gastroenterology 105:1909–1911

    PubMed  Google Scholar 

  • Kvols LK, Reubi JC, Horisberger U, Moertel CG, Rubin J, Charboneau JW (1992) The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J Biol Med 65:505–518

    PubMed  Google Scholar 

  • Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PPM, Lamberts SWJ (1993a) Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 20:283–292

    PubMed  Google Scholar 

  • Kwekkeboom DJ, Reubi JC, Lamberts SWJ, Bruining HA, Mulder AH, Oei HY, Krenning EP (1993b) In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 76:1413–1417

    PubMed  Google Scholar 

  • Kwekkeboom DJ, Urk H van, Pauw BK, Lamberts SWJ, Kooij PPM, Hoogma RP, Krenning EP (1993c) Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 34:873–878

    PubMed  Google Scholar 

  • Kwekkeboom DJ, Kho GS, Lamberts SWJ, Reubi J-C, Laissue JA, Krenning EP (1994) The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 21:1106–1113

    PubMed  Google Scholar 

  • Lamberts SWJ, Koper JW, Reubi JC (1987) Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest 17:281–287

    PubMed  Google Scholar 

  • Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP (1990a) Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 323:1246–1249

    PubMed  Google Scholar 

  • Lamberts SWJ, Hofland LJ, Koetsveld PM van, Reubi JC, Bruining HA, Bakker WH, Krenning EP (1990b) Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab 71:566–574

    PubMed  Google Scholar 

  • Lamberts SWJ, Krenning EP, Klijn JG, Reubi J-C (1990c) The clinical use of somatostatin analogues in the treatment of cancer. Baillière's Clin Endocrinol Metab 4:29–49

    Google Scholar 

  • Lamberts SWJ, Krenning EP, Reubi JC (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrinol Rev 12:450–482

    Google Scholar 

  • Lastoria S, Vergara E, Varella P, Colao A, Ferone D, Longobardi S, Merola B, Salvatore M (1993) In vivo detection of human somatostatin receptor positive tumors by indium-111 octreotide. J Nucl Med 34:219P-220P

    Google Scholar 

  • Laubenbacher C, Flierdt E van de, Alt A, Wagner-Manslau C, Kruschke C, Avril N, Langhammer HR, Pabst HW (1993) Biodistribution of In-111 pentetreotide in patients with carcinoid tumors. J Nucl Med 34:41P

  • Lee JD, Kim DI, Lee JT, Chang JW, Park CY (1995) Indium-111-pentetreotide imaging in intra-axial brain tumors: comparison with thallinum-201 SPECT and MRI. J Nucl Med 36:537–541

    PubMed  Google Scholar 

  • Lipp RW, Silly H, Ranner G, Dobnig H, Passath A, Leb G, Krejs GJ (1995) Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy. J Nucl Med 36:13–18

    PubMed  Google Scholar 

  • Luyken C, Hildebrandt G, Scheidhauer K, Krisch B, Schicha H, Klug N (1994) 111Indium (DTPA-octreotide) scintigraphy in patients with cerebral gliomas. Acta Neurochir (Wien) 127:1–2

    Google Scholar 

  • Mabile L, Egroizard B, Houzard C, Sassolas G, Itti R (1993) Is Indium-111-labelled somatostatin analog more accurate than 131-I-MIBG in the diagnosis of metastatic malignant phaeochromocytomas? Eur J Nucl Med 20:933

    Google Scholar 

  • Macaulay VM, Smith IE, Everard MJ, Teale JD, Reubi JC, Millar JL (1991) Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. Br J Cancer 64:451–456

    PubMed  Google Scholar 

  • Macke HR, Smith-Jones P, Maina T, Stolz B, Albert R, Bruns C, Reist H (1993) New octreotide derivatives for in vivo targeting of somatostatin receptor-positive tumors for single photon emission computed tomography (SPECT) and positron emission tomography (PET). Horm Metab Res [Suppl] 27:12–17

    Google Scholar 

  • Magnani P, Paganelli G, Sognini C, Colombo P, Faglia G, Fazio F (1993) Combined use of 111In labeled pentetreotide and 3-step ISG with anti-Cg A moAb in the diagnosis of pituitary adenomas. J Nucl Med 34:114P

    Google Scholar 

  • Mahler C, Verhelst J, Longueville M de, Harris A (1990) Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol 33:261–269

    Google Scholar 

  • Maini CL, Tofani A, Sciuto R, Carapella C, Cioffi R, Crecco M (1993a) Somatostatin receptors in meningiomas: a scintigraphic study using 111In-DTPA-d-Phe-1-octreotide. Nucl Med Commun 14:550–558

    PubMed  Google Scholar 

  • Maini CL, Tofani A, Venturo I, Pigorini F, Sciuto R, Semprebene A, Boni S, Giunta S, Lopez M (1993b) Somatostatin receptor imaging in small cell lung cancer using 111In-DTPA-octreotide: a preliminary study. Nucl Med Commun 14:962–968

    PubMed  Google Scholar 

  • Martin-Comin J, Roca M, Mairal L, Fernandez-Sevilla A, Petit J, Thakur ML (1993) 99m Tc-Sandostatin scanning in the evaluation of thoracic lymphomas. Eur J Nucl Med 20:884

    Google Scholar 

  • Mekkonen Y, Raue F, Zink A, Ziegler R (1993) Long-term exposure to SMS 201-995 inhibits proliferation and calcitonin release in neoplastic C-cells. Horm Metab Res 25:528–531

    PubMed  Google Scholar 

  • Modigliani E, Cohen R, Joannidis S, Siame-Mourot C, Guliana JM, Charpentier G, Cassulo D, Bentata Pesayre M, Tabarin A, Roger P, Caron P, Guillausseau PJ, Lalau JD, Touniaire J, Bayard F, Aufèvre P, James-Deidier A, Calmettes C (1992) Results of longterm continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin Endocrinol 36:183–186

    Google Scholar 

  • Moertel CG (1987) An odyssey in the land of small tumors. J Clin Oncol 5:1503–1522

    Google Scholar 

  • O'Byrne K, Lyons D, Istarabadi M, O'Donnell C, O'Hare N, Freyne P, Clancy L, Ennis J, Prichard E, McGovern D, Luke D, Carney D (1993) Scintigraphic imaging of lung tumours with a radiolabelled somatostatin analogue. Nucl Med Commun 14:234

    Google Scholar 

  • O'Byrne KJ, Ennis JT, Freyne PJ, Clancy LJ, Prichard JS, Carney DN (1994) Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue. Br J Cancer 69:762–766

    PubMed  Google Scholar 

  • Parmar H, Phillips RH, Lightman SL, (1993) Somatostatin analogues: mechanism of action. In: Höffken K (eds) Peptides in oncology. II. Somatostatin analogues and bombesin antagonists. Springer, Berlin Heidelberg New York, pp 1–24

    Google Scholar 

  • Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB (1994) All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun 198:605–612

    PubMed  Google Scholar 

  • Peters AM, Hammond P, Wynick D, Arka A, Calam J, Wade A (1993) Localisation of gastroenteropancreatic tumors with In-111 somatostatin analogue. J Nucl Med 34:41P

    Google Scholar 

  • Platz D, Lüdecke DK, Lübeck M, Gratz KF (1993) Preoperative indium-111-octreoscan-SPECT in pituitary adenomas: correlation with pretreatment results. Eur J Nucl Med 20:933

    Google Scholar 

  • Pollak M, Gallant K, Poisson R, Harris A (1992) Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial. Metabolism 41 [Suppl 2]:119–120

    PubMed  Google Scholar 

  • Postema PTE, Herder WW de, Oei HY, Kwekkeboom DJ, Lamberts SWJ, Hennemann G, Krenning EP (1994) [In-111-DTPA-d-Phe1]octreotide scintigraphy (In-SMS) in non-medullary thyroid carcinoma. J Nucl Med 35:163P

    Google Scholar 

  • Prévost G, Foehrlé E, Thomas F, Pihan I, Veber N, Starzec A, Israël L (1991) Growth of human breast cancer cell lines is inhibited by the somatostatin analog BIM23014. Endocrinology 129:323–329

    PubMed  Google Scholar 

  • Reubi JC (1985) New specific radioligand for one subpopulation of brain somatostatin receptors. Life Sci 36:1829–1836

    PubMed  Google Scholar 

  • Reubi JC (1992) Somatostatin receptors in the gastrointestinal tract in health and disease. Yale J Biol Med 65:493–503

    PubMed  Google Scholar 

  • Reubi JC (1995a) Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 36:1825–1835

    PubMed  Google Scholar 

  • Reubi JC (1995b) In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 36:1846–1853

    PubMed  Google Scholar 

  • Reubi JC, Landolt AM (1989) The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 68:844–850

    PubMed  Google Scholar 

  • Reubi JC, Torhorst J (1989) The relationship between somatostatin, epidermal growth factor, and steroid hormone receptors in breast cancer. Cancer 64:1254–1260

    PubMed  Google Scholar 

  • Reubi JC, Hacki WH, Lamberts SW (1987) Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab 65:1127–1134

    PubMed  Google Scholar 

  • Reubi JC, Maurer R, Werder K von, Torhorst J, Klijn JGM, Lamberts SWJ (1987) Somatostatin receptors in human endocrine tumors. Cancer Res 47:551–558

    PubMed  Google Scholar 

  • Reubi JC, Horisberger U, Lang W, Koper JW, Braakman R, Lamberts SW (1989) Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol 134:337–344

    PubMed  Google Scholar 

  • Reubi JC, Kvols L, Krenning E, Lamberts SW (1990a) Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 39 [Suppl 2]: 78–81

    PubMed  Google Scholar 

  • Reubi JC, Waser B, Foekens JA, Klijn JG, Lamberts SW, Laissue J (1990b) Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors. Int J Cancer 46:416–420

    PubMed  Google Scholar 

  • Reubi JC, Waser B, Sheppard M, Macaulay V (1990c) Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: relationship to EGF-receptors. Int J Cancer 45:269–274

    PubMed  Google Scholar 

  • Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E (1991) Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 64:567–573

    PubMed  Google Scholar 

  • Reubi JC, Laissue J, Krenning E, Lamberts SW (1992a) Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 43:27–35

    PubMed  Google Scholar 

  • Reubi JC, Waser B, Khosla S, Kvols L, Goellner JR, Krenning EP, Lamberts SWJ (1992b) In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 74:1082–1089

    PubMed  Google Scholar 

  • Reubi JC, Waser B, Hagen M van, Lamberts SW, Krenning EP, Gebbers JO, Laissue JA (1992c) In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer 50:895–900

    PubMed  Google Scholar 

  • Reubi JC, Waser B, Horisberger U, Krening EP, Lamberts SWJ, Gebbers JO, Gersbach P, Laissue JA (1993) In vitro autoradiographic and in vivo scintigraphic localization of somatostain receptors in human lymphatic tissue. Blood 82:2143–2151

    PubMed  Google Scholar 

  • Reubi JC, Horisberger U, Laissue J (1994) High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? Int J Cancer 56:681–688

    PubMed  Google Scholar 

  • Rufini V, Salvatori M, Saletnich I, Martino G, Maussier ML, Corsello SM, Troncone L (1994) Radiolabelled somatostatin analog (SMS) in medullary thyroid ca. (MTC): a comparison with Tc-99m-(V)DMSA and I-123-MIBG. Preliminary results. Eur J Nucl Med 21:864

    Google Scholar 

  • Sagman U, Mullen JB, Kovacs K, Kerbel R, Ginsberg R, Reubi JC (1990) Identification of somatostatin receptors in human small cell lung carcinoma. Cancer 66:2129–2133

    PubMed  Google Scholar 

  • Sarda L, Mundler O, Zini JM, Duet M, Berolatti B, Benelhadj S, Tobelem G, Grall Y (1994) 111In-octreoscan somatostatin receptor scintigraphy in malignant lymphomas. Eur J Nucl Med 21:727

    Google Scholar 

  • Sautter-Bihl ML, Dörr U, Schilling F, Treuner J, Bihl H (1994) Somatostatin receptor imaging: a new horizon in the management of neuroblastoma. Semin Oncol 21 [Suppl 13]:38–41

    Google Scholar 

  • Scheidhauer K, Göhring U, Scharl A, Voth E, Theissen P, Schomäcker K, Bolte A, Schicha H (1993a) Somatostatin-receptor-imaging in breast tumors. Eur J Nucl Med 20:973

    Google Scholar 

  • Scheidhauer K, Hildebrandt G, Luyken C, Schomacker K, Klug N, Schicha H (1993b) Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences. Horm Metab Res [Suppl] 27:59–62

    Google Scholar 

  • Schirmer WJ, O'Dorisio TM, Schirmer TP, Mojzisik CM, Hinkle GH, Martin EW (1993) Intraoperative localization of neuroendocrine tumors with 125I-Tyr(3)-octreotide and a hand-held gamma-detecting probe. Surgery 114:745–751

    PubMed  Google Scholar 

  • Sciuk J, Schültz S, Gellner R, Brandau W, Schober O (1992) Detection of endocrine active tumours of the gastrointestinal tract (GEP-tumours) by means of In-111 pentatreotide scintigraphy. Eur J Nucl Med 19:607

    Google Scholar 

  • Scopinaro F, Delle Fave G, Schillaci O, Di Macio L, Annibale B, Corleto V, Gualdi G, Passaro E, Brasso N, Materia A, Polettini E, Centi Colella A (1993) Detection of gastrinoma with111In Octreoscan. Eur J Nucl Med 20:846

    Google Scholar 

  • Steinert H, Lehnert H, Bockisch A, Beyer J, Hahn K (1993) Detection of malignant phaeochromocytoma tumour sites by 111-Inoctreotide scintigraphy. Eur J Nucl Med 20:843

    Google Scholar 

  • Stoffel M, Jamar F, Martiat P, Leners N, Beckers C, Ferrant A, Pauwels S (1994) Somatostatin receptor imaging in lymphomas. J Nucl Med 35:131P

    Google Scholar 

  • Stolz B, Smith-Jones PM, Russer G, Albert R, Briner U, Mäcke H, Weckbecker G, Bruns C (1995) Somatostatin receptor-mediated radiotherapy of cancer—preclinical evaluation of the concept. J Nucl Med 36:114P

    Google Scholar 

  • Tenenbaum F, Lumbroso J, Schlumberger M, Muré A, Plouin PF, Caillou B, Parmentier C (1995) Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant phaeochromocytoma. J Nucl Med 36:1–6

    PubMed  Google Scholar 

  • Ur E, Mather SJ, Bomanji J, Ellison D, Britton KE, Grossman AB, Wass JA, Besser GM (1992) Pituitary imaging using a labelled somatostatin analogue in acromegaly. Clin Endocrinol 36: 147–150

    Google Scholar 

  • Ur E, Bomanji J, Mather SJ, Britton KE, Wass JA, Grossman AB, Besser GM (1993) Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide. Clin Endocrinol 38: 501–506

    Google Scholar 

  • Vanhagen PM, Krenning EP, Reubi JC, Mulder AH, Bakker WH, Oei HY, Lowenberg B, Lamberts SWJ (1993) Somatostatin analogue scintigraphy of malignant lymphomas. Br J Haematol 83:75–79

    PubMed  Google Scholar 

  • Verhoeff NPLG, Meylaerts SAG, Miedema AR, Royen EA van, Assies J, Zant FM van der (1993) Somatostatin receptor imaging in the pituitary using [In-111 DTPA]-octreotide and high resolution SPECT. J Nucl Med 34:41P-42P

    Google Scholar 

  • Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W, Valent P (1994) Vasoactive peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 331:1116–1121

    PubMed  Google Scholar 

  • Virgolini I, Kurtaran A, Raderer M, Leimer M, Angelberger P, Havlik E, Li S, Scheithauer W, Niederle B, Valent P, Eichler HG (1995) Vasoactive peptide-receptor scintigraphy. J Nucl Med 36:1732–1739

    PubMed  Google Scholar 

  • Waddington WA, Kettle AG, Heddle RM, Coakley AJ (1994) Intraoperative localization of recurrent medullary carcinoma of the thyroid using indium-111 pentetreotide and a nuclear surgical probe. Eur J Nucl Med 21:363–364

    PubMed  Google Scholar 

  • Walker MD (1973) Brain and peripheral nervous system tumors. In: Holland JF, Frei E (eds) Cancer medicine, Lea & Febiger, Philadelphia, pp 1385–1417

    Google Scholar 

  • Weckbecker G, Tolcsvai L, Liu R, Bruns C (1993) Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995). Metabolism 41 [Suppl 2]:99–103

    Google Scholar 

  • Weinel RJ, Neuhaus C, Stapp J, Klotter HJ, Trautmann ME, Arnold R, Josef K, Rothmund M (1992) Somatostatin in der präoperativen Therapie und postoperativen Diagnostik eines Patienten mit Verner-Morrison-Syndrom. Langenbecks Arch Chir 377:345–347

    PubMed  Google Scholar 

  • Westlin JE (1992) Studies in nuclear medicine of the in vivo localization and characterisation of neuroendocrine tumours. Thesis, University of Uppsala

  • Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S (1992a) Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA 89:251–255

    PubMed  Google Scholar 

  • Yamada Y, Reisine T, Law SF, Ihara Y, Kubota A, Kagimoto S, Seino M, Seino Y, Bell GI, Seino S (1992b) Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol 6:2136–2142

    PubMed  Google Scholar 

  • Yasuda K, Espinosa R3, Davis EM, Le Beau MM, Bell GI (1993) Human somatostatin receptor genes: localization of SSTR5 to human chromosome 20p11.2. Genomics 17:785–786

    PubMed  Google Scholar 

  • Zant FM van der, Verhoeff NPLG, Rehman CJ, Tiel-Buul MC van (1993) Clinical experience with OctreoScan. Nucl Med Commun 14:234

    Google Scholar 

Download references

Author information

Author notes

  1. R. Valkema

    Present address: Dijkzigt Department of Nuclear Medicine, University Hospital Rotterdam, Rotterdam, The Netherlands

Authors and Affiliations

  1. Department of Diagnostic Radiology and Nuclear Medicine, University Hospital, Building 1, C4Q, P.O. Box 9600, 2300 RC, Leiden, The Netherlands

    R. Valkema, J. Steens & E. K. J. Pauwels

  2. Department of Clinical Oncology, Leiden University Hospital, Leiden, The Netherlands

    F. J. Cleton

Authors
  1. R. Valkema
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Steens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. J. Cleton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. K. J. Pauwels
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Valkema, R., Steens, J., Cleton, F.J. et al. The diagnostic utility of somatostatin receptor scintigraphy in oncology. J Cancer Res Clin Oncol 122, 513–532 (1996). https://doi.org/10.1007/BF01213548

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01213548

Key words

Search

Navigation